Drug Profile
Research programme: acute coronary syndrome therapeutics - AstraZeneca
Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Shionogi
- Class Cardiovascular therapies; Macromolecular substances
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute coronary syndromes
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Acute coronary syndromes in Japan
- 08 Oct 2014 Preclinical trials in Acute coronary syndromes in Japan (unspecified route)